Form 4: OS Therapies Director Granted 140,000 Stock Options

OS Therapies Inc. Director Olivier Roger Jarry received a grant of 140,000 stock options with an exercise price of $1.80 per share, vesting in one year.

Summary

• Olivier Roger Jarry, a Director of OS Therapies Inc. (OSTX), was granted 140,000 stock options.
• The options have an exercise price of $1.80 per share.
• The grant date for these options was October 21, 2025.
• The options will vest in full on the one-year anniversary of the grant date, specifically October 21, 2026, provided Mr. Jarry is still serving as a director.
• The expiration date for these stock options is October 21, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally viewed as a neutral to slightly positive action as it aligns interests, but does not indicate significant operational or financial news.

Positives

• The stock option grant aligns the director's long-term interests with those of the shareholders, incentivizing performance and growth.
• It serves as a retention mechanism for key board members, ensuring continued leadership and expertise.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity.

Risks

• The value of the stock options is subject to the future market price volatility of OS Therapies Inc.'s common stock.
• The options will only vest if Olivier Roger Jarry continues to serve as a director until October 21, 2026, posing a risk of forfeiture if service terminates early.

Future Outlook

The future outlook for the granted options is contingent on the director's continued service with OS Therapies Inc. until October 21, 2026, for full vesting, and the company's stock performance relative to the $1.80 exercise price.

Management Comments

• Olivier Jarry was granted options to purchase 140,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement.

Industry Context

The grant of stock options to directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies like OS Therapies Inc., to attract, retain, and incentivize board members by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice in the U.S. public markets, especially for companies in the biotech sector where long-term value creation is paramount.
• The vesting schedule, typically over one to four years, is also common, with a one-year cliff vesting as seen here being a straightforward approach for director grants.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised in the future, but also benefits from increased alignment of director's interests with long-term company performance.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.

Next Steps

• The stock options are scheduled to vest in full on October 21, 2026, provided Olivier Roger Jarry remains a director.

Key Dates

Keywords

OS Therapies Inc., OSTX, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Olivier Jarry